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Neuroprotective role of PrPC against kainate-
induced epileptic seizures and cell death 
depends on the modulation of JNK3 activation 
by GluR6/7–PSD-95 binding
ABSTRACT Cellular prion protein (PrPC) is a glycosyl-phosphatidylinositol–anchored glyco-
protein. When mutated or misfolded, the pathogenic form (PrPSC) induces transmissible 
spongiform encephalopathies. In contrast, PrPC has a number of physiological functions in 
several neural processes. Several lines of evidence implicate PrPC in synaptic transmission and 
neuroprotection since its absence results in an increase in neuronal excitability and enhanced 
excitotoxicity in vitro and in vivo. Furthermore, PrPC has been implicated in the inhibition of 
N-methyl-d-aspartic acid (NMDA)–mediated neurotransmission, and prion protein gene (Prnp) 
knockout mice show enhanced neuronal death in response to NMDA and kainate (KA). In this 
study, we demonstrate that neurotoxicity induced by KA in Prnp knockout mice depends on 
the c-Jun N-terminal kinase 3 (JNK3) pathway since Prnpo/oJnk3o/o mice were not affected by 
KA. Pharmacological blockage of JNK3 activity impaired PrPC-dependent neurotoxicity. Fur-
thermore, our results indicate that JNK3 activation depends on the interaction of PrPC with 
postsynaptic density 95 protein (PSD-95) and glutamate receptor 6/7 (GluR6/7). Indeed, 
GluR6–PSD-95 interaction after KA injections was favored by the absence of PrPC. Finally, 
neurotoxicity in Prnp knockout mice was reversed by an AMPA/KA inhibitor (6,7-dinitroqui-
noxaline-2,3-dione) and the GluR6 antagonist NS-102. We conclude that the protection 
afforded by PrPC against KA is due to its ability to modulate GluR6/7-mediated neurotrans-
mission and hence JNK3 activation.
INTRODUCTION
The abnormal processing of cellular prion protein (PrPC) gives rise to 
PrPSC, or pathogenic prion, which is the etiologic agent of several 
transmissible spongiform encephalopathies (reviewed in Aguzzi 
et al., 2007; Aguzzi and Calella, 2009; Linden et al., 2008). These 
devastating encephalopathies are characterized by severe histolog-
ical changes, including extensive neuronal death, reactive gliosis, 
and neuroinflammation, concomitant to the accumulation of the ag-
gregated misfolded form of PrPC in affected brains. Although neces-
sary for prion propagation and infectivity (Weissmann et al., 1994), 
the repertoire of physiological roles of PrPC remains to be fully de-
termined. Indeed, PrPC has been implicated in a wide range of neu-
ral functions, such as copper homeostasis (Brown et al., 1997, 1998; 
Vassallo and Herms, 2003), neurotransmission (Maglio et al., 2004; 
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Prestori et al., 2008; Rangel et al., 2009), stem-cell proliferation 
and differentiation (Steele et al., 2006), malignant glioma prolifera-
tion (Erlich et al., 2007), neurite outgrowth (Chen et al., 2003; 
Santuccione et al., 2005), and, more recently, putative cross-talk be-
tween neurodegenerative diseases (Lauren et al., 2009; Gavin et al., 
2010; Gunther and Strittmatter, 2010).
Early in vitro studies with prion protein gene Prnpo/o mice (Zürich I) 
(Bueler et al., 1992) showed that cultured Prnpo/o neurons were 
more prone to die than Prnp+/+ neurons after serum withdrawal or 
other treatments (Kuwahara et al., 1999). Subsequent studies (Brown 
et al., 2002; Rambold et al., 2008; Aude-Garcia et al., 2011) indi-
cated that PrPC might play a neuroprotective function in the context 
of excitotoxic lesions. Indeed, it was demonstrated in rats that Prnp 
is overexpressed in ischemic brains and protects cortical neurons 
after ischemia (McLennan et al., 2004; Shyu et al., 2005; Spudich 
et al., 2005; Weise et al., 2006; Mitteregger et al., 2007). In fact, cells 
overexpressing PrPC show increased toxicity after endoplasmic re-
ticulum stress (Anantharam et al., 2008). Neuroprotective effects of 
PrPC after central nervous system insults have been associated with 
both extracellular and intracellular effectors (e.g., the stress-induced-
phosphoprotein 1) (Zanata et al., 2002) and are mediated by PI3K-
mTOR signaling (Martins et al., 2010; Roffe et al., 2010). However, 
although it is involved in Alzheimer’s disease (Lauren et al., 2009), 
PrPC does not act as a major modulator in a panel of neurodegen-
erative disease models (Steele et al., 2009).
In neurons, PrPC has been localized in axons at the synapse 
(Fournier et al., 2000; Fournier, 2008), which might be consistent 
with reports of deficits in neurotransmission in Prnp knockout mice 
(Maglio et al., 2004, 2006; Khosravani et al., 2008; Prestori et al., 
2008; Rangel et al., 2009). Indeed, PrPC knockout mice are more 
prone to cell death after kainate (KA) injections than are Prnp+/+ ani-
mals (Walz et al., 1999; Rangel et al., 2007, 2009). In addition, Prnpo/o 
neurons are also highly susceptible to acute N-methyl-d-aspartic 
acid (NMDA) or KA treatment in hippocampal slices (Rangel et al., 
2007; Khosravani et al., 2008). These findings suggest that PrPC can 
modulate signaling cascades by activating stress-protective path-
ways, or by inhibiting cytotoxic pathways (reviewed in Westergard 
et al., 2007; Nicolas et al., 2009). Although the exact mechanism(s) 
are unknown, the neuroprotective function may be associated with 
differential expression of glutamate receptor subunits or the modu-
lation of ligand/receptor affinities (Maglio et al., 2004; Khosravani 
et al., 2008; Rangel et al., 2009). In particular, it remains to be estab-
lished whether PrPC alters KA receptor–mediated neurotransmission 
at the neuron membrane. In fact, PrPC-binding proteins include, 
among others, membrane receptors (Rutishauser et al., 2009), and 
two recent studies reported cell-specific effects of glutamate and 
the role of PrPC in these processes. Indeed, group I metabotropic 
glutamate receptors are involved in the transduction of cellular sig-
nals triggered by PrPC, which modulates neurite outgrowth (Beraldo 
et al., 2011). In addition, in NMDA-mediated toxicity, the protective 
role of PrPC is mediated by the silencing of NMDA receptors con-
taining N-methyl-d-aspartate receptor subtype 2 (NR2D) subunits 
(Khosravani et al., 2008).
In a previous study, we reported the increased presence of phos-
phorylated c-Jun N-terminal kinase 3 (JNK) in dying pyramidal neu-
rons in the CA1 of the hippocampus of Prnp knockout mice after KA 
treatment (Rangel et al., 2007). Here we show that KA-induced ex-
citotoxicity in Prnp knockout mice depends on JNK3 activity, by 
developing a double-knockout mouse lacking PrPC and JNK3 ex-
pression and analyzing it by using gene expression and pharmaco-
logical approaches. Furthermore, we propose a mechanism by 
which PrPC regulates the KA receptor function through interaction, 
at the postsynaptic level, with the glutamate receptor 6/7 (GluR6/7) 
and the postsynaptic density 95 protein (PSD-95), which in turn 
modulates JNK3 activity.
RESULTS
Enhanced susceptibility to KA-induced seizures in Prnp 
knockout mice and its reversion in Prnpo/oJnk3o/o mice
The thresholds for onset of seizure behavior in response to identi-
cal intraperitoneal KA injections (6 mg/kg body weight) in the four 
mouse genotypes Prnpo/oJnk3+/+, Prnp+/+Jnk3o/o, Prnp+/+Jnk3+/+, 
and Prnpo/oJnk3o/o were analyzed. After the first KA injection, 
Prnpo/oJnk3+/+ animals developed profound hypoactivity and im-
mobility (grades I–II). After successive injections, hyperactivity 
(grade III) and scratching (grade IV) were often observed. Some 
mice progressed to a loss of balance control (grade V) and further 
chronic whole-body convulsions (grade VI). The bouncing activity 
commonly referred to as ‘‘popcorn’’ behavior was included in grade 
VI. After the behavioral study, mice were numbered and kept in 
separate boxes until histological or biochemical studies; see later 
discussion. Twelve hours after KA treatment, Prnp+/+Jnk3+/+ and 
Prnp+/+Jnk3o/o animals showed normal behavior. KA-treated 
Prnpo/oJnk3o/o mice displayed hypoactivity, immobility, and sensi-
tivity to external stimuli (e.g., box handling) (Table 1).
Prnpo/oJnk3+/+ mice were highly susceptible to KA, showing a 
greater number (from five to eight) of severe seizures (grade VI). In 
addition, they maintained grade IV–VI seizures for 2–3 h after the 
first episode, whereas and Prnp+/+Jnk3+/+ and Prnpo/oJnk3o/o mice 
displayed only grade III seizure. Furthermore, three Prnpo/oJnk3+/+ 
animals died during the experiments. These data corroborate previ-
ous results (Walz et al., 1999; Rangel et al., 2007, 2009) indicating 
increased sensitivity to KA in Prnp knockout mice. We established 
that the minimal concentration of KA required to induce seizures in 
the Prnp+/+Jnk3+/+ animals was 35–40 mg/kg body weight, which is 
similar to that required for Prnp+/+Jnk3+/o. At this concentration, all 
Prnpo/oJnk3+/+ animals died shortly after a second injection. These 
results suggested an active role of JNK3 in Prnpo/o susceptibility to 
KA. Indeed, Prnp+/+Jnk3o/o and Prnp+/+Jnk3+/o mice were not af-
fected by KA treatment as described (Yang et al., 1997).
Decreased seizures in Prnpo/oJnk3o/o mice correlated with 
lower number of dying cells in the hippocampus
Protein expression was analyzed by Western blot (Figure 1A), which 
showed that PrPC expression was similar in Prnp+/+Jnk3+/+ and 
Prnp+/+Jnk3o/o mice. In addition, JNK3 expression was similar in 
Prnp+/+Jnk3+/+ and Prnpo/oJnk3+/+ mice, and neither of these proteins 
was detected in the double-knockout mice, as expected (Figure 1A). 
Next we analyzed in more detail the time course of the seizure 
score after KA injection (Figure 1B). Prnpo/oJnk3+/+ mice showed 
maximum scores (V–VI) between 90 and 180 min after the first KA 
injection. To determine whether the severity of seizure observed 
in Prnpo/oJnk3+/+ correlates with neuronal loss and reactive glial 
changes in the hippocampus after KA injection, we carried out sev-
eral histochemical and immunohistochemical analyses (Figure 1, C 
and D).
First, we analyzed the pattern of neurodegeneration in the 
Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, and Prnpo/oJnk3o/o mice 24 h after 
KA treatment by using Fluoro-Jade B staining (Schmued and 
Hopkins, 2000; Figure 1C). Numerous Fluoro-Jade B–positive py-
ramidal neurons were observed in the CA1 and CA3 regions of 
Prnpo/oJnk3+/+ hippocampus. In the other genotypes Fluoro-Jade 
B labeling was rare and generally pale (Figure 1C). To further 
corroborate the death of these neurons, we applied in parallel 
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sections the in situ nick-translation technique with biotinylated-UTP 
to determine the DNA fragmentation level (TUNEL technique, by 
using ApopTag kit; Heatwole, 1999; Figure 1D). Distribution of 
TUNEL-positive nuclei largely correlated with the pattern of Fluoro-
Jade B labeling observed in the CA1 and CA3 of Prnpo/oJnk3+/+ 
mice (Figure 1, D and E). Cell counts showed statistical significance 
(see Materials and Methods for details) when comparing data of 
Prnpo/oJnk3+/+ mice with any of the other two genotypes.
Genotype. Animal Number of seizures Number of blinkings Behavioral stages Prioritary stage
Prnp+/+Jnk3+/+ 1 1 0 I–II II
Prnp+/+Jnk3+/+ 2 0 0 I–II II
Prnp+/+Jnk3+/+ 3 1 1 I–II II
Prnp+/+Jnk3+/+ 4 1 0 I–II II
Prnp+/+Jnk3+/+ 5 0 0 I–II II
Prnp+/+Jnk3+/+ 6 0 0 I–II II
Prnp+/+Jnk3+/+ 7 0 0 I–II II
Prnp+/+Jnk3+/+ 8 0 0 I–II II
Prnp+/+Jnk3+/+ 9 0 0 I–II II
Prnp+/+Jnk3+/+ 10 1 0 I–III II
Prnp+/+Jnk3+/+ 11 0 0 I–II II
Prnp+/+Jnk3+/+ 12 0 0 I–II II
Prnpo/oJnk3+/+ 13 8 4 I–VI †
Prnpo/oJnk3+/+ 14 5 3 I–VI IV–VI
Prnpo/oJnk3+/+ 15 6 4 I–VI V–VI
Prnpo/oJnk3+/+ 16 6 3 I–VI †
Prnpo/oJnk3+/+ 17 5 2 I–VI V–VI
Prnpo/oJnk3+/+ 18 6 3 I–VI †
Prnpo/oJnk3+/+ 19 6 4 I–VI V–VI
Prnpo/oJnk3+/+ 20 5 2 I–VI IV–VI
Prnpo/oJnk3+/+ 21 4 2 I–VI V–VI
Prnpo/oJnk3+/+ 22 8 5 I–VI V–VI
Prnpo/oJnk3+/+ 23 6 3 I–VI IV–VI
Prnpo/oJnk3+/+ 24 7 5 I–VI V–VI
Prnpo/oJnk3o/o 25 1 1 I–II II
Prnpo/oJnk3o/o 26 2 0 I–II II
Prnpo/oJnk3o/o 27 1 0 I–II II
Prnpo/oJnk3o/o 28 0 0 I–II II
Prnpo/oJnk3o/o 29 0 0 I–II II
Prnpo/oJnk3o/o 30 0 0 I–II II
Prnpo/oJnk3o/o 31 0 0 I–II II
Prnpo/oJnk3o/o 32 2 2 I–III II
Prnpo/oJnk3o/o 33 0 0 I–II II
Prnpo/oJnk3o/o 34 1 1 I–II II
Prnpo/oJnk3o/o 35 0 0 I–II II
Prnpo/oJnk3o/o 36 0 0 I–II II
Prnp+/+Jnk3+/+ 37 0 0 I–II II
Prnp+/+Jnk3+/+ 38 0 0 I–II II
Prnp+/+Jnk3+/+ 39 0 0 I–II II
Prnp+/+Jnk3+/+ 40 0 0 I–II II
See Results for stage classification.
TABLE 1: Effect of KA-induced status epilepticus and death in Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, Prnpo/oJnk3o/o, and Prnp+/+Jnk3o/o mice.
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Acute down-regulation of PrPC 
expression in Prnp+/+Jnk3+/+ primary 
neuronal cultures increased 
susceptibility to KA
We examined whether the neurotoxic ef-
fects of KA are modified when PrPC expres-
sion levels are acutely altered in Prnp+/+Jnk3+/+ 
neurons. Thus, Prnp+/+Jnk3+/+ primary corti-
cal neurons were infected with a lentivirus 
carrying a small interfering RNA (siRNA) in-
terference sequence for Prnp. Cells infected 
with lentivirus showed an 81% decrease in 
PrPC expression (Figure 2A). After exposure 
to KA, cells infected with lentivirus showed a 
statistically significant 29% decrease in sur-
vival (Figure 2B) compared with parallel en-
hanced green fluorescent protein (eGFP)–
infected cultures (Figure 2B). Thus, although 
similar data were previously described in 
neuroblastoma cells (N2A) using interfer-
ence RNA against Prnp (Rangel et al., 2007), 
this is the first observation of KA-mediated 
cell death after acute PrPC down-regulation 
in Prnp+/+Jnk3+/+ neurons. This finding rein-
forces the notion that decreased expression 
of PrPC compromises neuronal viability after 
acute KA treatment.
Differential activation of JNK3 and 
extracellular regulated kinases 1/2 in 
Prnpo/oJnk3+/+ mouse hippocampus 
treated with KA
Because genetic deletion of Jnk3 on a 
Prnpo/o background overcomes the intrinsic 
susceptibility to KA of PrPC-deficient mice, 
we next developed several experiments to 
identify changes in JNK3 activation in the 
hippocampus after KA treatment (Figure 3). 
Mice were injected with KA as described 
and killed 6 h later (see Materials and 
Methods for details). Activation of extracel-
lular regulated kinase (ERK) 1/2, JNK3, 
c-Jun, and p53 was analyzed in protein 
samples from the hippocampus of treated 
mice by Western blot and compared with 
vehicle-injected mice. In the absence of 
KA, ERK1/2 was activated in Prnpo/oJnk3+/+ 
and Prnpo/oJnk3o/o hippocampus compared 
with Prnp+/+Jnk3+/+ mice (Figure 3A). These 
data corroborate the reported data of 
FIGuRE 1: KA-dependent sensitivity, seizure behavior, neurotoxicity and apoptosis in the 
different genotypes studied. (A) Western blot of JNK3, PrPC, and tubulin in protein extract from 
the hippocampi of the different mouse strains used in this study (Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, 
Prnpo/oJnk3o/o, and Prnp+/+Jnk3o/o); tubulin was used as a loading control. (B) Comparison of 
seizure responses in littermates of Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, Prnpo/oJnk3o/o, and 
Prnp+/+Jnk3o/o mice to intraperitoneal injection of KA (6 mg/kg body weight) or 0.1 M PBS. 
KA-injection timing is indicated below the graph. Seizures were scored as indicated in Materials 
and Methods. Eight mice in each group were observed and scored to determinate the time-
dependent seizure score. (C) Photomicrographs showing examples of the pattern of Fluoro-Jade 
B and DAPI staining of hippocampal region of Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, and Prnpo/oJnk3o/o 
mice after 24 h of KA treatment. Dying cells positive for Fluoro-Jade B are located in the 
pyramidal cell layer of Prnpo/oJnk3+/+ (arrows). (D) Examples of TUNEL-positive cells in CA1–CA3 
hippocampal regions of Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, and Prnpo/oJnk3o/o mice after 24 h of KA 
treatment. (E) Quantification of Fluoro-Jade B and TUNEL-positive cells in the CA1 and CA3 
regions of the hippocampus in Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, and Prnpo/oJnk3o/o mice after 24 h 
of KA treatment. Results are obtained from 
nine mice per genotype. DG, dentate gyrus; 
CA1–3, hippocampal regions 1 and 3; gl, 
granule cell layer; h, hilus; ml, molecular layer; 
sl, stratum lucidum; slm, stratum lacunosum-
moleculare; so, stratum oriens; sp, stratum 
pyramidale; sr, stratum radiatum. Scale bar, 
C, top, 200 μm; C, bottom, 100 μm; D, 
100 μm. Asterisks in E indicate statistical 
significance (***p < 0.001, ANOVA test).
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ERK1/2 activation in Prnp knockout mice (Brown et al., 2002). In 
parallel to the phosphorylation of ERK1/2 in all genotypes after KA 
treatment, an increase in p-JNK3 and p-c-Jun Ser63 was observed 
in Prnpo/oJnk3+/+ hippocampus (Figure 3A). This phosphorylation 
was undetectable in vehicle-treated mice and in Prnp+/+Jnk3+/+, as 
well as in Prnpo/oJnk3o/o mice (Figure 3A) and Prnp+/+Jnk3o/o 
(unpublished data), as expected. Total c-Jun protein was slightly 
increased in Prnp+/+Jnk3+/+ but strongly increased in both 
Prnpo/oJnk3+/+ and Prnpo/oJnk3o/o after KA treatment (Figure 3A). 
Finally, p53, which was recently reported to be activated in a JNK-
dependent manner in dying hippocampal neurons after glutamate 
and/or KA (Choi et al., 2011), was phosphorylated at Ser-15 and 
activated in Prnpo/oJnk3+/+ hippocampus after KA treatment.
These results suggest that signaling pathways other than the 
JNK3 pathway are activated after KA treatment. Indeed, we deter-
mined the cellular expression of ERK1/2 in detail in treated mice 
(Figure 3, B and C). p-ERK1/2 staining was strong in hippocam-
pal mossy fibers at the stratum lucidum in Prnpo/oJnk3+/+ and 
Prnpo/oJnk3o/o, with low levels in Prnp+/+Jnk3+/+, after 24 h of KA 
treatment. Double-labeling techniques with glial fibrillary acidic pro-
tein (GFAP) and p-ERK1/2 revealed a second group on p-ERK1/2–
stained cells at CA1 and CA3 regions (Figure 3C). However, detailed 
observation of astroglial cells in these mutants revealed an increased 
reactivity of astrocytes in Prnpo/oJnk3+/+ hippocampus (relevant 
GFAP content and thick glial expansions), in contrast to moderate 
reactivity in Prnpo/oJnk3o/o and absence in Prnp+/+Jnk3+/+ mice 
(Figure 3D). Thus these data indicate that most p-ERK1/2 staining 
observed in Prnpo/oJnk3+/+ and Prnpo/oJnk3o/o after KA treatment is 
mainly associated with mossy fiber staining with the participation of 
GFAP-reactive cells.
The JNK3 pathway is implicated in c-fos and c-jun activation af-
ter glutamate treatment (Brami-Cherrier et al., 2007). To discrimi-
nate the particular contribution of JNK3 to c-jun and c-fos expres-
sion in our experiments, we performed quantitative real-time 
PCR (RT-qPCR; Figure 4). Data obtained demonstrate that both 
c-jun and c-fos were overexpressed in the hippocampus of 
Prnpo/oJnk3+/+ mice 6 h after KA administration (4.10- and 49.2-fold 
increase, respectively; Figure 4A). Deletion of Jnk3 in Prnpo/o mice 
offset the c-jun and c-fos increase by 34 and 25% respectively, com-
pared with Prnpo/oJnk3+/+ levels. These results support the idea that 
other KA-activated pathways are the main contributors to the over-
expression of both early genes. To examine this hypothesis, we 
analyzed the differential expression of cyclooxygenase-2 (cox-2), a 
molecular target of JNK activation in neurodegeneration and in-
flammation activated by activator protein-1 (AP-1; Hunot et al., 
2004). RT-qPCR of cox-2 revealed statistically significant overexpres-
sion in the Prnpo/oJnk3+/+ hippocampus after KA treatment. Further-
more, stronger decrease of cox-2 was observed in Prnpo/oJnk3o/o 
(60% compared with those reported by c-jun and c-fos) (Figure 4B). 
The results indicate that the absence of Jnk3 is not the only factor 
mediating the early changes in gene expression mediated by KA.
Pharmacological inhibition of JNK in Prnpo/oJnk3+/+ 
hippocampal slices overcame the neurotoxic effect of KA
To ascertain whether neurotoxic differences are cell specific or as-
sociated with an increased glutamatergic input from the entorhinal 
cortex, we performed a parallel study in isolated hippocampal slices 
(Figure 5). Prnpo/oJnk3+/+ and Prnp+/+Jnk3+/+ hippocampal slices 
were treated with KA or phosphate-buffered saline (PBS), following 
the addition (when indicated) of two different JNK inhibitors: the 
pharmacological inhibitor SP600125 and the peptide TAT-JIP, a spe-
cific inhibitor derived from the minimal JNK-binding region of the 
scaffold protein JNK-interacting protein 1 (JIP-1) coupled to the 
short cell-permeable TAT sequence (Bonny et al., 2001; Figure 5A). 
After propidium iodide (PI) incubation, we observed few randomly 
distributed, labeled cells in the CA1–CA3 of Prnp+/+Jnk3+/+–derived 
hippocampal slices. However, Prnpo/oJnk3+/+ slices showed a statis-
tically significant 71% increase of PI fluorescence compared to 
Prnp+/+Jnk3+/+ cultures (Figure 5B). The inhibition of JNK activity 
with SP600125 and TAT-JIP in Prnpo/oJnk3+/+–derived slices de-
creased the fluorescence levels by 54 and 42%, respectively, com-
pared with parallel KA-treated slices without the inhibitors (Figure 5, 
B and C). These data indicate that increased cell death of hip-
pocampal Prnpo/oJnk3+/+ neurons is associated with intrinsic synap-
tic properties.
Coimmunoprecipitation of PrPC with PSD-95 and GluR6/7 
in the PSD fractions
To investigate the participation of PrPC in the neurotoxic ef-
fects of KA, we examined whether PrPC exerts its neuroprotec-
tive function by modulating the intracellular signaling trig-
gered by KA receptor after ligand binding. Because neuronal 
depolarization mediated by KA requires the interaction of the 
GluR6/7 subunit of KA receptor with PSD-95 and MLK3 to form 
a trimeric complex (Pei et al., 2006; Li et al., 2010), we analyzed 
biochemically the distribution of GluR6/7 and PrPC in the 
Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, and Prnpo/oJnk3o/o hippo campus 
and whether changes in JNK3 alter the normal distribution of 
FIGuRE 2: Decrease in PrPC expression–enhanced KA neurotoxicity 
in primary hippocampal neurons. Primary hippocampal neurons were 
infected with lentivirus containing eGFP or siRNA for Prnp for 24 h. 
Next, neurons were treated with 150 μM KA for 8 h, and cell viability 
was analyzed after further 24 h with the WST-1 method as indicated in 
Materials and Methods. (A) Western blot for PrPC and tubulin 
expression after lentiviral infection with eGFP and siRNA Prnp. Note 
the decrease of the PrPC expression after lentiviral infection vs. 
vehicle and eGFP. (B) Histogram illustrating cell viability infection and 
KA exposure. No differences were observed between vehicle and 
eGFP. Data are expressed as fold increase ± SEM of three 
independent experiments. Asterisks in B indicate statistical 
significance (**p < 0.01, ANOVA test).
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PrPC. Enriched PSD fractions were isolated from the hippocam-
pus of Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, and Prnpo/oJnk3o/o mice 6 h 
after administration of KA and processed for GluR6/7, PSD-95, 
and PrPC by Western blot (Figure 6A). 
Correct purification of the PSD fractions 
was corroborated since the percentage of 
PSD-95 in this fraction was 91.6% of total 
PSD-95. Results revealed no changes in 
subcellular distribution of these proteins 
among genotypes. As expected, PrPC was 
detected in all cell compartments but en-
riched in PSD fractions, where GluR6/7 
and PSD-95 were also found.
These results suggested a putative in-
teraction between GluR6/7 and PrPC. To 
explore this possibility, we performed 
coimmunoprecipitation experiments from 
whole Prnp+/+Jnk3+/+ hippocampus protein 
extracts and PSD fractions using two differ-
ent PrPC antibodies (6H4 and SAF61; see 
Materials and Methods; Figure 6B). Re-
sults indicated that PrPC interacts with 
PSD-95 and GluR6/7 both in whole-hip-
pocampus extracts and in purified PSD. As 
expected, both interactions were stronger 
in the PSD fraction (Figure 6B). Taken to-
gether, these results implicate PrPC in the 
binding of PSD-95 with the KA receptor 
containing GluR6/7. This would allow the 
formation of the ternary complex (GluR6/7–
PSD-95–MLK3), which in turn activates the 
JNK3 pathway. Thus, to determine this, we 
immunoprecipitated PSD-95 in hippocam-
pal protein extracts from Prnp+/+Jnk3+/+ and 
Prnpo/oJnk3+/+ mice to measure the amount 
of GluR6/7 coimmunoprecipitated in the 
presence or absence of KA (Figure 6C). Im-
munoblots showed that the interaction be-
tween GluR6/7 and PSD-95 was higher in 
the hippocampus of Prnpo/oJnk3+/+ com-
pared with Prnp+/+Jnk3+/+ mice in the pres-
ence of KA (1.01 vs. 2.13, respectively; 
Figure 6C). Taken together, these data indi-
cate that, in the absence of PrPC, KA treat-
ment increased the binding of GluR6/7-
containing KA receptors to PSD-95, which 
correlates with increased activation of 
JNK3.
Increased KA-mediated neurotoxicity 
in Prnpo/o mice was reversed 
by 6,7-dinitroquinoxaline-2,3-dione 
and NS-102
To examine the role of GluR6/7 in 
KA-induced neurotoxicity in Prnp+/+Jnk3+/+ 
and Prnpo/oJnk3+/+ mice, we injected 
the AMPA/KA inhibitor 6,7-dinitroquinox-
aline-2,3-dione (DNQX) and the GluR6 
antagonist NS-102 (Verdoorn et al., 
1994) prior to the intraperitoneal injection 
with KA (Figure 7). DNQX inhibits AMPA/
KA receptors in vivo (Alford and Grillner, 
1990) and inhibits JNK3 activation after excitotoxic insults (Tian 
et al., 2005), and NS-102 is a good functional antagonist of 
GluR6 in vivo in response to excitotoxic insults (Tian et al., 2005; 
FIGuRE 3: KA-induced neurotoxicity in Prnp knockout hippocampal mouse correlates with 
JNK3 activation. (A) Western blot for p-JNK, JNK3, p-ERK1/2, ERK1/2, p-c-Jun, c-Jun, p-p53, 
and tubulin from hippocampus extracts of Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, and Prnpo/oJnk3o/o mice 
after 6 h of KA treatment (6 mg/kg body weight). KA-induced neurotoxicity in the Prnpo/oJnk3+/+ 
hippocampus is cell-specific and dependent on JNK3 activity. (B) Photomicrograph illustrating 
the pattern of p-ERK1/2 in the different phenotypes after 24 h of KA treatment. Notice the 
relevant increase of p-ERK1/2 in Prnpo/oJnk3+/+ and Prnpo/oJnk3o/o hippocampus. (C) High 
magnification of the CA1 region of hippocampus from Prnpo/oJnk3+/+, after 24 h of KA 
treatment, immunostained with p-ERK1/2 and GFAP antibodies. Note that numerous cells are 
double labeled (arrows). (D) Photomicrograph illustrating examples of the CA1 region of the 
three genotypes analyzed after 24 h of KA treatment and immunostained for GFAP. Levels of 
reactive glia are not completely abolished by the genetic deletion of Jnk3. Abbreviations as in 
Figure 1. Scale bars, B, 150 μm; C, 100 μm; and D, 100 μm.
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Hu et al., 2008; Chen et al., 2009). First, we counted the seizures 
and the blinking episodes in treated mice (Figure 7A). Pharma-
cological treatments indicate that preinjection with DNQX and, 
more effectively, with NS-102 reduced the number of all of the 
episodes counted in Prnpo/oJnk3+/+ mice. Prnp+/+Jnk3+/+ mice 
were almost insensitive to KA, as described earlier (Figure 7A). 
Again, both treatments reduced the number of Fluoro-Jade 
B–positive cells in the hippocampus (Figure 7B) and the pres-
ence of p-c-Jun in Prnpo/oJnk3+/+ hippocampus in Western blots 
(Figure 7C). In addition, we examined the effect of DNQX and 
NS-102 on c-Fos expression, which was overexpressed in the 
hippocampus of Prnpo/oJnk3+/+ mice after KA injections (see 
earlier discussion). Blockage of both AMPA/KA receptors and 
GluR6 prevented c-Fos overexpression in CA1 (Figure 7D) 
and increased immunostaining of p-ERK1/2 in mossy fibers of 
Prnpo/oJnk3+/+ (Figure 7E). Measure of the fluorescence in the 
mossy fibers with ImageJ software (square regions of interest of 
75 × 75 μm, six measures per section) indicates a statistically 
significant reduction of 80 and 75% of p-ERK1/2 staining after 
DNQX and NS-102 treatments respective (Figure 7F).
DISCUSSION
Differential participation of ERK1/2, 
JNK3 kinases, and early gene 
expression in KA-mediated neuronal 
death in Prnpo/o mice
In this study we demonstrate that abolition 
of JNK3 activity (either genetically or phar-
macologically) blocks the neurotoxic activity 
induced by KA in Prnpo/o mice. These data 
indicate that the signal for neuronal cell 
death in Prnp knockout mice is mainly asso-
ciated with JNK3 activity. In addition, to 
avoid the effects of the increased oxidative 
phenotype in absence of Prnp (Wong et al., 
2001; Brown et al., 2002), we show that an 
acute decrease in PrPC expression in cul-
tured neurons from Prnp+/+Jnk3+/+ mice also 
increased their susceptibility to KA. In fact, 
absence of Jnk3 completely blocked the 
epileptogenic effects of KA in Prnp+/+ mice, 
and the original Jnk3o/o mice were charac-
terized as being resistant to KA, with similar 
scores to those reported here (Yang et al., 
1997; de Lemos et al., 2010).
Although basal p-ERK1/2 is higher in 
Prnpo/o mice (Brown et al., 2002; Chiarini 
et al., 2002; Nicolas et al., 2007; Rangel 
et al., 2007; and present results), treatment 
with KA induces overphosphorylation of 
ERK1/2, which is not affected by the ab-
sence of Jnk3. In contrast, ERK1/2 activation 
is abolished in Jnk3o/o mice 3 h after KA 
treatment (de Lemos et al., 2010). Thus it is 
reasonable to consider that changes in 
p-ERK1/2 in Prnpo/oJnk3o/o mice after KA 
treatment are mainly associated with the 
Prnpo/o background. p-ERK1/2 is expressed 
by mossy fibers of granule cells, as well as 
by reactive, GFAP-positive astrocytes, after 
KA treatment; in contrast, JNK activation 
mainly takes place in dying neurons (CA1–
CA3 pyramidal neurons; Rangel et al., 2007). 
Our histological and biochemical analyses demonstrate that an in-
creased number of GFAP-positive cells can be seen in the double-
knockout hippocampus without relevant cell death. These data also 
contrast with those obtained with Jnk3o/o mice (Yang et al., 1997; de 
Lemos et al., 2010). Although we cannot rule out an effect of acti-
vated p-ERK1/2/GFAP–positive astrocytes on JNK-activated dying 
neurons, it seems that intrinsic ERK1/2 phosphorylation (which is not 
blocked by deletion of Jnk3) in granule cells could participate in the 
sustained c-jun overexpression in response to KA in a Prnpo/o back-
ground. On the other hand, c-jun was upregulated in Prnpo/oJnk3o/o 
mice after KA treatment, but no neurodegeneration was observed 
when compared with both Prnp+/+Jnk3+/+ and Prnpo/oJnk3+/+ mice in 
brain sections when examined by different methods (Fluoro-Jade B 
or TUNEL). Thus c-Jun overexpression cannot be associated with 
cell death and needs to be phosphorylated by JNK3 to induce cell 
death. Indeed, JNK3 phosphorylates c-Jun at Ser-63 and Ser-73, 
and abrogation of c-Jun phosphorylation using alanine mutants for 
c-Jun at Ser-63 and Ser-73 confers resistance to epileptic seizures 
and neuronal apoptosis induced by KA (Behrens et al., 1999). On 
the other hand, c-fos was upregulated only in dying Prnpo/oJnk3+/+ 
FIGuRE 4: RT-qPCR of (A) c-jun and c-fos and (B) cox-2 from hippocampal RNA extracts of 
Prnp+/+Jnk3+/+, Prnpo/oJnk3+/+, and Prnpo/oJnk3o/o mice treated with KA (6 mg/kg body weight) 
or buffer for 6 h. Data (mean ± SEM) represent mean fold induction obtained in three 
independent experiments. GAPDH was used as the housekeeping gene. Data are referred 
with Prnp+/+Jnk3+/+ in each histogram in the absence or presence of KA. Data are expressed 
as fold change ± SEM. Asterisks in A and B indicate statistical significance (** p < 0.01, 
*** p < 0.001, ANOVA test).
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cells, and Jnk3 deletion did not totally decrease c-fos levels, sug-
gesting its implication in different KA-signaling mechanisms. In ad-
dition, our data also implicate p53 in these results since phosphory-
lation of p53 follows the activity pattern of 
JNK3 (only activated in Prnpo/oJnk3+/+ after 
KA treatment). This is compatible with the 
recent proposal that p53 activation after 
glutamatergic stimulus depends on JNK ac-
tivity (Choi et al., 2011).
JNK3-mediated signaling activates the 
AP-1 complex, which triggers the expres-
sion of early response genes such as c-fos or 
c-jun, as well as the up-regulation of cox-2, 
which is involved in the inflammatory re-
sponse after KA treatment (Tu and Bazan, 
2003). In fact, pharmacological inhibition or 
genetic deletion of cox-2, but not Cox-1, in-
creases susceptibility to KA-induced hip-
pocampal excitotoxicity (Toscano et al., 
2008). In our study, cox-2 was up-regulated 
after KA treatment in Prnpo/oJnk3+/+, whereas 
in Prnpo/oJnk3o/o, cox-2 expression was 
largely reduced (up to 60%), indicating a re-
duction in inflammatory responses in the 
double-knockout mice. Indeed, a direct re-
lation between JNK activity, c-Jun phospho-
rylation, and cox-2 up-regulation has been 
demonstrated in several models (Waetzig 
et al., 2005), and the up-regulation of Cox-2 
mediated by JNK is necessary and required 
for neurodegeneration in a mouse model of 
Parkinson disease (Hunot et al., 2004).
A putative role of PrPC at the neuronal 
membrane as modulator of GluR6/7–
mediated neurotransmission and JNK3 
activity
GluR6 knockout and Jnk3o/o mice are resis-
tant to KA treatment. In fact, it has been 
reported that GluR6 binds to PSD-95, and 
this binding is necessary to trigger GluR6-
dependent neurotransmission (Savinainen 
et al., 2001) due to the formation of a sta-
ble trimeric complex GluR6–PSD-95–MLK3 
(Li et al., 2010). In this study we found large 
colocalization of PrPC with GluR6/7 in the 
PSD. Moreover, Prnp deletion favors the 
interaction between PSD-95 and GluR6/7 
in the presence of KA. Taken together, our 
results suggest that absence of PrPC en-
hances the interaction of the ternary com-
plex PSD-95 and GluR6 and most probably 
MLK3 at the synapse, thus enabling GluR6-
mediated intracellular signaling. This in 
turn leads to JNK3 activation among that 
of other kinases.
As mentioned, PrPC has been detected 
in axon and synaptic contacts, although 
whether its location is presynaptic or post-
synaptic is not fully determined (Fournier 
et al., 2000; Fournier, 2008). Here we report 
that a fraction of PrPC localized to the PSD, 
where neurotransmitter receptors are located. Recent studies in-
dicate that PrPC is a constitutive basal protector against NMDA-
mediated toxicity. Deletion of the Prnp gene induces enhanced 
FIGuRE 5: KA-enhanced neurotoxicity in Prnp knockout organotypic slices correlates with JNK3 
activation. (A) Schematic diagram illustrating the experimental procedure. The hippocampi of 
Prnp+/+Jnk3+/+ and Prnpo/oJnk3+/+ animals were dissected and cultured in transwells until drug 
treatment and afterward analyzed by PI uptake. (B) Examples of PI uptake in organotypic 
hippocampal slice cultures from Prnp+/+Jnk3+/+ and Prnpo/oJnk3+/+ mice treated with 0.1 M PBS or 
150 μM KA for 2 h in the presence or absence of JNK inhibitors SP600125 (20 μM) and TAT-JIP 
(10 μM) as indicated. Twenty-four hours after treatment slices were incubated with PI. Note the 
incorporation of PI in dying cells in KA-treated slices from Prnpo/oJnk3+/+ mice. (C) Histogram 
illustrating quantitative results of A. Histograms represent the mean ± SEM of three 
independent experiments. Asterisks in C indicate statistical significance (***p < 0.001, ANOVA 
test). Abbreviations as in Figure 1. Scale bars, B, 100 μm.
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2009), which demonstrated that enhanced 
neurotoxicity to KA in hippocampal slices of 
Prnpo/o mice has both a KA receptor and a 
NMDA receptor component. However, the 
molecular mechanism by which PrPC inhibits 
NMDA and KA receptors is unclear. PrPC 
may either influence agonist binding, favor 
the closed state of the channel, or interfere 
with the signal transmission, thus forming a 
negative modulator complex (Steele, 2008). 
In any case PrPC expression does not appear 
to be critical for neuronal glutamate trans-
port (Thais et al., 2006). Irrespective of the 
molecular mechanisms responsible for these 
effects, our data indicate that PrPC (both for 
KA and NMDA receptors) inhibits gluta-
matergic neurotransmission and that the 
absence of PrPC enhances neurotoxic sig-
naling. Furthermore, it is tempting to specu-
late on a similar protective effect in other 
brain injuries that share a similar activation 
mechanism through the receptor complex 
GluR6/7–PSD-95–MLK3, where signaling is 
transmitted downstream into the JNK3 
pathway. Further studies would be needed 
to confirm this hypothesis. In this regard, in-
creased levels of PrPC in plasma have been 
found after acute ischemia in rats and in hu-
man stroke patients (Mitsios et al., 2007). 
Indeed, Weise et al. (2004) suggested that 
the extent of the up-regulation of PrPC in 
ischemic brains depends on the severity of 
ischemia and may therefore reflect the ex-
tent of ischemia-induced neuronal damage. 
We believe that discerning the functional 
roles of PrPC at the synapse, as well as its 
specific interacting partners in normal and 
pathological conditions at the synapse, 
would help us to understand neurotoxicity 
in synapse-associated neurodegenerative 
diseases and ischemic processes. Figure 8 
shows a general scheme depicting the role 
of the GluR6/7–JNK3 signaling pathway in 
mediating the neurotoxic effects of KA in 




Prnp knockout mice Zürich I (Prnpo/o) were 
purchased from the European Mouse 
Mutant Archive (EMMA, Monterotondo, It-
aly). Prnpo/o mice were backcrossed with 
C57BL6J mice from 10 generations up to 
obtain 92–95% of C57BL6J microsatellite 
markers (Charles River background analysis) from the previous 46–
48% of the Zürich I mice. Jnk3 knockout mice were generated as 
described elsewhere (Yang et al., 1997). Double-knockout animals 
(Prnpo/oJnk3o/o) were generated by crossing backcrossed Prnpo/o 
mice with Jnk3o/o mice (with 70–75% of C57BL6J microsatellite 
markers). To avoid putative background-specific differences be-
tween mice, all of the experiments were conducted using littermates 
prolonged NMDA-evoked currents in hippocampal neurons, which 
increases neuronal excitability and glutamate excitotoxicity (Khosra-
vani et al., 2008). The same authors described changes in some 
parameters associated with AMPA/KA–mediated miniature inhibi-
tory postsynaptic currents and γ-aminobutyric acid A–mediated 
miniature inhibitory postsynaptic currents (Khosravani et al., 2008). 
These findings are in concordance with our data (Rangel et al., 2007, 
FIGuRE 6: PrPC interacts with PSD-95 and glutamate receptor 6/7. (A) Hippocampus from 
KA-injected Prnp+/+Jnk3+/+, Prnpo/o Jnk3+/+, and Prnpo/oJnk3o/o mice was fractionated by 
differential centrifugation in order to purify PSD fraction. Fractions were separated by SDS–
PAGE, followed by immunoblotting with the indicated antibodies. (B) Extracts from total 
hippocampus or hippocampal PSD fraction from Prnp+/+Jnk3+/+ mouse were immunoprecipitated 
using two PrPC antibodies (6H4 and SAF61). Immunoprecipitated samples were separated by 
SDS–PAGE, followed by immunoblotting with the indicated antibodies. (C) Prnp+/+Jnk3+/+ and 
Prnpo/oJnk3+/+ mice were injected with KA (6 mg/kg body weight) or PBS and analyzed for 4 h. 
Hippocampi were dissected, and cellular extracts were immunoprecipitated with control and 
anti–PSD-95 antibodies. Immunoprecipitated samples were developed by Western blot with the 
anti–GluR6/7 antibody. Densitometry values are standardized with Prnp+/+Jnk3+/+ in untreated 
cultures, and quantification was represented as fold change ± SEM. Notice the increase of 
GluR6/7 labeling after PSD immunoprecipitation in Prnpo/oJnk3+/+ after KA treatment.
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glutamate receptor 6/7 (anti–GluR6/7) antibodies and Fluoro-Jade 
B were from Millipore (Billerica, MA). SAF61 antibody was from 
Spi-Bio (Cayman Chemical, Massy, France), and 6H4 antibody was 
from Prionics (Schlieren, Switzerland). SYBR green was from Roche 
(Basel, Switzerland).
KA injections
To induce convulsive nonlethal seizures in mice, we developed a 
progressive KA treatment by administering several consecutive in-
traperitoneal (i.p.) injections of the glutamate agonist KA dissolved 
in 0.1 M PBS, pH 7.2 (Rangel et al., 2007). PBS 0.1 M, pH 7.2 (vehi-
cle), was injected as control. Adult animals (Prnpo/oJnk3+/+; 2–3 
mo old) were weighed and i.p. injected with two injections of KA 
(6 mg/kg body weight) at time 0 and 30 min. Seizure intensity after 
KA injections was evaluated as described previously during the 4 h 
after the first KA injection (Peng et al., 1997; Lee et al., 2000). Tissue 
samples were analyzed at the indicated times.
derived from heterozygous (Prnp+/oJnk3+/o) parents. Specific primers 
for Prnp genotyping were designed in our laboratory based on the 
original P10 and P3 primers described elsewhere (Bueler et al., 
1992). The Jnk3 knockout mice were genotyped as described else-
where (Kuan et al., 1999). A total of 45 litters were used in the pres-
ent study. All experimental procedures were carried out in accor-
dance with the guidelines of the Spanish Ministry of Science and 
Technology following European standards.
Reagents and antibodies
KA, PI, SP600125, TAT-JIP peptide, DNQX, NS-102, and antitubu-
lin antibody were from Sigma (Poole, United Kingdom). Anti–
p-ERK1/2, total anti–ERK1/2, p-c-Jun (Ser-63), anti–p-JNK, anti–
p-p53 (Ser-15). and total anti-JNK3 antibodies were from Cell 
Signaling (Beverly, MA). Anti–c-Jun antibody was from Santa Cruz 
Biotechnology (Santa Cruz, CA). Anti–c-Fos was from Calbiochem 
(Darmstadt, Germany). Postsynaptic density 95 (anti–PSD-95) and 
FIGuRE 7: AMPA/kainate receptor inhibition decreased the KA-enhanced neurotoxicity in Prnpo/oJnk3+/+ mice. 
(A) Seizures and blinking events for KA-injected mice. Injections were carried out with KA (6 mg/kg body weight), PBS, 
and the inhibitors DNQX and NS-102 as indicated on the timeline. (B) Examples of Fluoro-Jade B and DAPI staining in 
hippocampal CA1 region of Prnpo/oJnk3+/+ mice 24 h after injection of KA in the presence or absence of DNQX and 
NS-102. (C) Western blots of p-c-Jun, c-Jun, and tubulin from the hippocampus of the animals 4 h after injection of KA in 
presence or absence of DNQX and NS-102. (D) Photomicrographs of c-Fos immunoreactivity in the hippocampal CA1 
region of Prnpo/oJnk3+/+ mice 24 h after injection of KA in the presence or absence of DNQX and NS-102. 
(E) Photomicrographs of p-ERK1/2 immunoreactivity in the hippocampus of Prnpo/oJnk3+/+ mice 24 h after injection of 
KA in the presence or absence of DNQX and NS-102. Representative images from three different experiments are 
shown. (F) Histogram illustrating quantitative results of the fluorescence levels analyzed in E. Data are represented as 
mean ± SEM. Asterisks indicate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001; ANOVA test). Abbreviations 
as in Figure 1. Scale bars, B, 100 μm; E, 200 μm.
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Fluoro-Jade B staining of dying neurons in brain sections
Coronal brain sections were obtained as described and rinsed for 
2 h in 0.1 M Tris, pH 7.4, mounted, and air dried at room tempera-
ture overnight. The next day, sections were pretreated for 3 min in 
absolute ethanol, followed by 1 min in 70% ethanol and 1 min in 
distilled water. They were then oxidized in a solution of 0.06% 
KMnO4 for 15 min. After three rinses of 1 min each in distilled water, 
the sections were incubated for 30 min in a solution of 0.001% 
Fluoro-Jade B (Chemicon) containing 0.01% of DAPI (Sigma) in 0.1% 
acetic acid. The slides were rinsed in deionized water for 3 min each, 
dried overnight, cleared in xylene, and cover-slipped with Eukitt 
(Merck, Darmstadt, Germany) and examined using an Olympus 
(Hamburg, Germany) BX61 epifluorescence microscope.
Neuronal primary cultures and treatments
Primary hippocampal neurons were prepared from the hippocam-
pus of perinatal (embryological day 18 to day of birth) animals. 
Briefly, hippocampal neurons were grown on dishes coated with 
poly-d-lysine (30 μg/ml) in Neurobasal medium supplemented with 
B27, 0.5 mM glutamine, 12.5 mM glutamate, and antibiotics (all 
purchased from Invitrogen, Carlsbad, CA). At 9 d in vitro (DIV), hip-
pocampal neurons were infected with lentivirus carrying the eGFP 
construct (Morales et al., 2008) or the siRNA for Prnp. Lentiviral par-
ticles were produced by transient transfection of 293FT cells with 
Lipofectamine 2000 (Invitrogen), using Mission short hairpin RNA 
prion protein NM_011170 (Sigma), the second-generation packag-
ing construct psPAX2 (Tronolab, Lausanne, Switzerland), and the 
envelope plasmid pMD2G (Tronolab). 293FT cells were cultured in 
DMEM supplemented with 10% fetal calf serum and without antibi-
otics before transfection. Medium was changed and supplemented 
with antibiotics after 6 h. Vector supernatants containing viral parti-
cles were harvested ∼24 and 48 h later and concentrated by ultra-
centrifugation (2 h at 26,000 × g at 4°C). After 5 d of infection, cul-
tured neurons were treated with KA (150 μM dissolved in 0.1 M PBS; 
for 8 h). After treatment, cultures were rinsed twice in KA-free cul-
ture medium. The next day, cultures were incubated for 2 h with 
WST-1 reagent (Roche), and the absorbance (450 nm) was measured 
in a multiwell plate reader (Merck ELISA System MIOS).
Organotypic slice cultures of hippocampus
Hippocampal slice cultures were prepared from day of birth as de-
scribed elsewhere (Stoppini et al., 1991, 1993; del Rio and Soriano, 
2010). Animals were anaesthetized, and brains were removed asep-
tically from the skull. Horizontal slices (325–350 μm thick) of the hip-
pocampus were obtained using a McIlwain tissue chopper (Mickle 
Laboratory, Guildford, United Kingdom). Sections were maintained 
and selected in cold MEM supplemented with glutamine (2 mM; 
MEM dissecting salt solution) for 45 min. Selected slices were then 
cultured using the membrane interface method (Stoppini et al., 
1991). Slices were placed on 30-mm-diameter sterile membranes 
(Millicell-CM, Millipore) and transferred to six-well tissue culture 
plates (Nunc, Roskilde, Denmark). Cultures were incubated with 
1.2 ml of culture medium (50% MEM, 25% horse serum, 25% Hank’s 
buffered salt solution, containing 2 mM glutamine and 0.04% 
NaHCO3, adjusted to pH 7.3). The membrane cultures were main-
tained in a humidified incubator at 37ºC in a 5% CO2 atmosphere. 
The medium was changed every 2 d. All culture reagents were pur-
chased from Invitrogen-Life Technologies (Merelbeke, Belgium).
Neuronal death after treatments in organotypic slice cultures 
was monitored by PI uptake (Rangel et al., 2007). After 9 d of cul-
ture, hippocampal slice cultures were serum deprived for 3 h, and 
150 μM of KA was added. Cultured were exposed to protein JNK 
Immunohistochemistry
After KA treatment, mice were perfused with phosphate buffered 
4% paraformaldehyde, pH 7.3, postfixed overnight in the same fixa-
tive, and cryoprotected in 30% sucrose. Coronal sections (30 μm 
thick) were obtained in a freezing microtome (Leica, Wetzlar, 
Germany). Free-floating sections were rinsed in 0.1 M PBS, and en-
dogenous peroxidases were blocked with 3% H2O2 and 10% meth-
anol dissolved in 0.1 M PBS. After extensive rinsing, sections were 
incubated in 0.1 M PBS containing 0.2% gelatin, 10% normal serum, 
0.2% glycine, and 0.2% Triton X-100 for 1 h at room temperature. 
Sections were then incubated overnight at 4°C with the distinct pri-
mary p-ERK1/2 and GFAP antibodies. After washing in 0.1 M PBS 
containing 0.2% Triton X-100, sections were incubated with Alexa 
Fluor 488– and/or Alexa Fluor 568–tagged secondary antibodies 
(1:200 diluted; Molecular Probes, Eugene, OR), washed in 0.1 M, 
PBS counterstained with 4′,6-diamidino-2-phenylindole (DAPI; 
1 μM in 0.1 M PBS; 10 min), and mounted in Fluoromount (Vector 
Labs, Burlingame, CA). Dying cells in histological sections were 
measured using the S7100 ApopTag peroxidase in situ apoptosis 
(TUNEL) detection kit, following the manufacturer’s instructions 
(Chemicon, Temecula, CA).
FIGuRE 8: Proposed scheme illustrating the neurotoxic effects of KA 
in mouse hippocampus in the absence of PrPC. In the absence of Prnp 
(knockout, siRNA), KA activates neurotoxic signaling in the 
hippocampal cells, favoring the interaction of PSD-95 with GluR6/7, 
inducing c-Jun and c-Fos overexpression and JNK3 activation, which, 
in turn, provokes the phosphorylation of c-Jun, leading to 
neurotoxicity and cell death.
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pal fractions, PSD fractions were diluted with RIPA buffer: 150 mM 
NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 
and 50 mM Tris, pH 8.0, up to 500 μl. Samples were processed as 
described earlier but using RIPA buffer instead of lysis buffer for im-
munoprecipitation washes. Proteins attached to Sepharose beads 
were eluted with SDS–PAGE sample buffer, subjected to SDS–PAGE, 
transferred to PVDF membranes, and probed with the GluR6/7 and 
PSD-95 antibodies.
RT-qPCR
RT-qPCR was performed on total RNA extracted with the mirVana 
isolation kit (Ambion, Austin, TX) from the hippocampus of analyzed 
mice. Purified RNAs were used to generate the corresponding cD-
NAs, which served as PCR templates for mRNA quantification. The 
primers used in this study for RT-qPCR validation are given in Sup-
plemental Figure S1. PCR amplification and detection were per-
formed with the Roche LightCycler 480 detector, using 2x SYBR 
Green Master Mix (Roche) as reagent, following the manufacturer’s 
instructions. The reaction profile was as follows: denaturation–acti-
vation cycle (95°C for 10 min) followed by 40 cycles of denaturation–
annealing–extension (95°C, 10 min; 72°C, 1 min; 98°C, continuous). 
mRNA levels were calculated using the LightCycler 480 software. 
The data were analyzed using the ΔΔCt method, which provides 
the target gene expression values as fold changes in the problem 
sample compared with a calibrator sample. Both problem and cali-
brator samples were normalized by the relative expression of a 
housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase 
[GAPDH]).
Statistical analysis
All data are presented as mean ± SEM. Pairwise one-way analysis of 
variance (ANOVA) with Newman–Keuls multiple comparisons test 
was used for comparison. The operations were performed using 
Systat Software (Chicago, IL) or Statgraphics (StatPoint Technolo-
gies, Warrenton, VA). Statistical significance was set at *p < 0.05, 
**p < 0.01, and ***p < 0.001.
inhibitors (SP600125 20 μM or TAT-JIP 10 μM) for 45 min before KA 
treatment. After treatment, slices were rinsed twice in KA-free 
culture medium. The next day, slices were incubated for 2 h with 
1 μg/ml of PI dissolved in culture medium. PI-treated slices were 
fixed for 1 h with 4% buffered paraformaldehyde, pH 7.2. After rins-
ing, cultures were mounted in Fluoromount and photodocumented 
in an Olympus confocal microscope. To determine the maximum PI 
fluorescence for quantification, total fluorescence in the pyramidal 
layer of the hippocampus was measured in a 500-μm segment of 
the layer in the CA1–CA3 regions after incubation with 10 mM glu-
tamate for 10 min, using Quantity One Imaging and Analysis soft-
ware (Bio-Rad Laboratories, Hemel Hempstead, United Kingdom).
PSD purification from mice hippocampus
The PSD fraction was purified from adult mice (10–12 mo old) as 
indicated (Coba et al., 2009). Briefly, tissue was weighed, and 1 ml 
of homogenization buffer (0.32 M sucrose, 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid [HEPES], pH 7.4, 2 mM EDTA, 
2.5 mM N-ethylmaleimide, containing protease and phosphatase 
inhibitors) was added for every 125 mg of tissue. Samples were ho-
mogenized in a glass–Teflon Dounce homogenizer (40 strokes) and 
centrifuged at 800 × g for 10 min at 4°C. The supernatant was cen-
trifuged at 10,000 × g for 15 min at 4°C, and pellet was resuspended 
in 0.5 ml of Triton buffer: 50 mM HEPES, pH 7.4, 2 mM EDTA, 5 mM 
EGTA, 1% Triton X-100, 2.5 mM N-ethylmaleimide, containing pro-
tease and phosphatase inhibitors) for every 125 mg of tissue. 
Samples were centrifuged at 50,000 × g for 30 min at 4°C, and the 
pellet was resuspended in 125 μl of resuspension buffer—50 mM 
Tris, pH 7.4, 1% SDS (when used for Western blotting) or 50 mM Tris, 
pH 8.5, 1% deoxycholate (when used for immunoprecipitation 
experiments)—for every 125 μg of tissue. Samples were incubated 
for 10 min at room temperature and centrifuged at 50,000 × g for 
15 min at 4°C.
Western blotting
Tissue samples from the hippocampus of KA-treated or vehicle-
treated mice were homogenized (10% wt/vol) in ice-cold lysis buf-
fer—50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% (wt/vol) Triton 
X-100, 0.5% (wt/vol) Nonidet P-40 (IGEPAL; Sigma), glycerol 10%, 
1 mM EDTA, 1 mM EGTA, and protease and phosphatase inhibi-
tors—using a motor-driven, glass–Teflon homogenizer in ice and 
centrifuged at 15,000 × g for 20 min. After protein quantification, 
tissue extracts were boiled in Laemmli sample buffer at 100ºC for 
5 min, followed by 6–10% SDS–PAGE electrophoresis, electrotrans-
ferred to polyvinylidene fluoride (PVDF) membranes (Millipore), and 
processed for immunoblotting and the ECL Plus kit (Amersham-
Pharmacia Biotech, GE Healthcare Bio-Sciences, Piscataway, NJ).
Immunoprecipitation
Cell extracts from total hippocampus or hippocampal PSD fractions 
were used for immunoprecipitation experiments. For total hip-
pocampus, cell extracts were processed as indicated for Western 
blot. After protein quantification, 1 mg of hippocampal protein ex-
tract was mixed with 10 μl of protein A/G–Sepharose (Sigma) previ-
ously equilibrated with lysis buffer—50 mM Tris–HCl, pH 7.4, 
150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl2, 10% glycerol, 1 mM 
phenylmethylsulfonyl fluoride, and protease and phosphatase in-
hibitors—for 2 h (preclearing). Samples were centrifuged, and the 
supernatant was mixed with the indicated immunoprecipitation an-
tibodies plus 10 μl of protein A/G–Sepharose overnight at 4°C. The 
immunocomplexes were washed in lysis buffer and once in lysis buf-
fer plus 0.25 M NaCl. For immunoprecipitation from PSD hippocam-
ACKNOWLEDGMENTS
We thank R. Rycroft for English language advice and D. Reginensi, 
I. Jimenez, and G. Tormen for technical assistance. This study was 
supported by the FP7-PRIORITY, the Spanish Ministry of Science and 
Innovation (BFU2009-10848), and the Generalitat de Catalunya 
(SGR2009-366) (J.A.D.R.) and grants from the Instituto Salud Carlos III 
(Madrid, Spain) (J.A.D.R. and I.F.) and SAF2010-21682 (C.C.). F.L. was 
supported by the FP7-PRIORITY. P.C. is supported by an FPI fellow-
ship from the Spanish Ministry of Science and Innovation. A.B. is a 
Sara Borrell Postdoctoral Researcher of the Instituto Salud Carlos III.
REFERENCES
Aguzzi A, Calella AM (2009). Prions: protein aggregation and infectious 
diseases. Physiol Rev 89, 1105–1152.
Aguzzi A, Heikenwalder M, Polymenidou M (2007). Insights into prion 
strains and neurotoxicity. Nat Rev Mol Cell Biol 8, 552–561.
Alford S, Grillner S (1990). CNQX and DNQX block non-NMDA synaptic 
transmission but not NMDA-evoked locomotion in lamprey spinal cord. 
Brain Res 506, 297–302.
Anantharam V, Kanthasamy A, Choi CJ, Martin DP, Latchoumycandane C, 
Richt JA, Kanthasamy AG (2008). Opposing roles of prion protein in 
oxidative stress- and ER stress-induced apoptotic signaling. Free Radic 
Biol Med 45, 1530–1541.
Aude-Garcia C, Villiers C, Candeias SM, Garrel C, Bertrand C, Collin V, 
Marche PN, Jouvin-Marche E (2011). Enhanced susceptibility of T lym-
phocytes to oxidative stress in the absence of the cellular prion protein. 
Cell Mol Life Sci 68, 687–696.
Volume 22 September 1, 2011 JNK3 signaling in PrPC neuroprotection | 3053 
Behrens A, Sibilia M, Wagner EF (1999). Amino-terminal phosphorylation of 
c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat 
Genet 21, 326–329.
Beraldo FH et al. (2011). Metabotropic glutamate receptors transduce sig-
nals for neurite outgrowth after binding of the prion protein to laminin 
gamma1 chain. FASEB J 25, 265–279.
Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF (2001). Cell-
permeable peptide inhibitors of JNK: novel blockers of beta-cell death. 
Diabetes 50, 77–82.
Brami-Cherrier K, Lavaur J, Pages C, Arthur JS, Caboche J (2007). Gluta-
mate induces histone H3 phosphorylation but not acetylation in striatal 
neurons: role of mitogen- and stress-activated kinase-1. J Neurochem 
101, 697–708.
Brown DR, Nicholas RS, Canevari L (2002). Lack of prion protein expression 
results in a neuronal phenotype sensitive to stress. J Neurosci Res 67, 
211–224.
Brown DR et al. (1997). The cellular prion protein binds copper in vivo. 
Nature 390, 684–687.
Brown DR, Schmidt B, Kretzschmar HA (1998). Effects of copper on survival 
of prion protein knockout neurons and glia. J Neurochem 70, 1686–1693.
Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, 
Prusiner SB, Aguet M, Weissmann C (1992). Normal development and 
behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 
356, 577–582.
Coba MP, Pocklington AJ, Collins MO, Kopanitsa MV, Uren RT, Swamy S, 
Croning MD, Choudhary JS, Grant SG (2009). Neurotransmitters drive 
combinatorial multistate postsynaptic density networks. Sci Signal 2, 
ra19.
Chen J et al. (2009). GluR6-containing KA receptor mediates the activation 
of p38 MAP kinase in rat hippocampal CA1 region during brain ischemia 
injury. Hippocampus 19, 79–89.
Chen S, Mange A, Dong L, Lehmann S, Schachner M (2003). Prion protein 
as trans-interacting partner for neurons is involved in neurite outgrowth 
and neuronal survival. Mol Cell Neurosci 22, 227–233.
Chiarini LB, Freitas AR, Zanata SM, Brentani RR, Martins VR, Linden R (2002). 
Cellular prion protein transduces neuroprotective signals. EMBO J 21, 
3317–3326.
Choi HJ, Kang KS, Fukui M, Zhu BT (2011). Critical role of the JNK-p53-
GADD45alpha apoptotic cascade in mediating oxidative cytotoxicity in 
hippocampal neurons. Br J Pharmacol 162, 175–192.
de Lemos L, Junyent F, Verdaguer E, Folch J, Romero R, Pallas M, Ferrer 
I, Auladell C, Camins A (2010). Differences in activation of ERK1/2 and 
p38 kinase in Jnk3 null mice following KA treatment. J Neurochem 114, 
1315–1322.
del Rio JA, Soriano E (2010). Regenerating cortical connections in a dish: 
the entorhino-hippocampal organotypic slice co-culture as tool for 
pharmacological screening of molecules promoting axon regeneration. 
Nat Protoc 5, 217–226.
Erlich RB, Kahn SA, Lima FR, Muras AG, Martins RA, Linden R, Chiarini LB, 
Martins VR, Moura Neto V (2007). STI1 promotes glioma proliferation 
through MAPK and PI3K pathways. Glia 55, 1690–1698.
Fournier JG (2008). Cellular prion protein electron microscopy: attempts/
limits and clues to a synaptic trait. Implications in neurodegeneration 
process. Cell Tissue Res 332, 1–11.
Fournier JG, Escaig-Haye F, Grigoriev V (2000). Ultrastructural localization of 
prion proteins: physiological and pathological implications. Microsc Res 
Tech 50, 76–88.
Gavin R, Ferrer I, del Rio JA (2010). Involvement of Dab1 in APP processing 
and beta-amyloid deposition in sporadic Creutzfeldt-Jakob patients. 
Neurobiol Dis 37, 324–329.
Gunther EC, Strittmatter SM (2010). Beta-amyloid oligomers and cellular 
prion protein in Alzheimer’s disease. J Mol Med 88, 331–338.
Heatwole VM (1999). TUNEL assay for apoptotic cells. Methods Mol Biol 
115, 141–148.
Hu WW, Du Y, Li C, Song YJ, Zhang GY (2008). Neuroprotection of hypo-
thermia against neuronal death in rat hippocampus through inhibit-
ing the increased assembly of GluR6-PSD95-MLK3 signaling module 
induced by cerebral ischemia/reperfusion. Hippocampus 18, 386–397.
Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, 
Flavell RA (2004). JNK-mediated induction of cyclooxygenase 2 is re-
quired for neurodegeneration in a mouse model of Parkinson’s disease. 
Proc Natl Acad Sci USA 101, 665–670.
Khosravani H et al. (2008). Prion protein attenuates excitotoxicity by inhibit-
ing NMDA receptors. J Cell Biol 181, 551–565.
Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA (1999). 
The Jnk1 and Jnk2 protein kinases are required for regional specific 
apoptosis during early brain development. Neuron 22, 667–676.
Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A, 
Matsumoto Y, Saeki K, Yokoyama T, Itohara S, Onodera T (1999). Prions 
prevent neuronal cell-line death. Nature 400, 225–226.
Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009). 
Cellular prion protein mediates impairment of synaptic plasticity by 
amyloid-beta oligomers. Nature 457, 1128–1132.
Lee JY, Park J, Kim YH, Kim DH, Kim CG, Koh JY (2000). Induction by 
synaptic zinc of heat shock protein-70 in hippocampus after kainate 
seizures. Exp Neurol 161, 433–441.
Li C, Xu B, Wang WW, Yu XJ, Zhu J, Yu HM, Han D, Pei DS, Zhang GY 
(2010). Coactivation of GABA receptors inhibits the JNK3 apoptotic 
pathway via disassembly of GluR6-PSD-95-MLK3 signaling module in 
KA-induced seizure. Epilepsia 51, 391–403.
Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR 
(2008). Physiology of the prion protein. Physiol Rev 88, 673–728.
Maglio LE, Martins VR, Izquierdo I, Ramirez OA (2006). Role of cellular prion 
protein on LTP expression in aged mice. Brain Res 1097, 11–18.
Maglio LE, Perez MF, Martins VR, Brentani RR, Ramirez OA (2004). Hip-
pocampal synaptic plasticity in mice devoid of cellular prion protein. 
Brain Res Mol Brain Res 131, 58–64.
Martins VR, Beraldo FH, Hajj GN, Lopes MH, Lee KS, Prado MM, Linden R 
(2010). Prion protein: orchestrating neurotrophic activities. Curr Issues 
Mol Biol 12, 63–86.
McLennan NF et al. (2004). Prion protein accumulation and neuroprotection 
in hypoxic brain damage. Am J Pathol 165, 227–235.
Mitsios N et al. (2007). Cellular prion protein is increased in the plasma 
and peri-infarcted brain tissue after acute stroke. J Neurosci Res 85, 
602–611.
Mitteregger G, Vosko M, Krebs B, Xiang W, Kohlmannsperger V, Nolting S, 
Hamann GF, Kretzschmar HA (2007). The role of the octarepeat region 
in neuroprotective function of the cellular prion protein. Brain Pathol 17, 
174–183.
Morales R, Riss M, Wang L, Gavin R, Del Rio JA, Alcubilla R, Claverol-Tinture 
E (2008). Integrating multi-unit electrophysiology and plastic culture 
dishes for network neuroscience. Lab Chip 8, 1896–1905.
Nicolas O, Gavin R, Braun N, Urena JM, Fontana X, Soriano E, Aguzzi A, 
del Rio JA (2007). Bcl-2 overexpression delays caspase-3 activation and 
rescues cerebellar degeneration in prion-deficient mice that overexpress 
amino-terminally truncated prion. FASEB J 21, 3107–3117.
Nicolas O, Gavin R, del Rio JA (2009). New insights into cellular prion 
protein (PrPc) functions: the “ying and yang” of a relevant protein. Brain 
Res Rev 61, 170–184.
Pei DS, Wang XT, Liu Y, Sun YF, Guan QH, Wang W, Yan JZ, Zong YY, Xu TL, 
Zhang GY (2006). Neuroprotection against ischaemic brain injury by a 
GluR6-9c peptide containing the TAT protein transduction sequence. 
Brain 129, 465–479.
Peng YG, Clayton EC, Means LW, Ramsdell JS (1997). Repeated indepen-
dent exposures to domoic acid do not enhance symptomatic toxicity 
in outbred or seizure-sensitive inbred mice. Fundam Appl Toxicol 40, 
63–67.
Prestori F, Rossi P, Bearzatto B, Laine J, Necchi D, Diwakar S, Schiffmann SN, 
Axelrad H, D’Angelo E (2008). Altered neuron excitability and synaptic 
plasticity in the cerebellar granular layer of juvenile prion protein knock-
out mice with impaired motor control. J Neurosci 28, 7091–7103.
Rambold AS, Muller V, Ron U, Ben-Tal N, Winklhofer KF, Tatzelt J (2008). 
Stress-protective signalling of prion protein is corrupted by scrapie 
prions. EMBO J 27, 1974–1984.
Rangel A, Burgaya F, Gavin R, Soriano E, Aguzzi A, Del Rio JA (2007). 
Enhanced susceptibility of Prnp-deficient mice to kainate-induced sei-
zures, neuronal apoptosis, and death: role of AMPA/kainate receptors. J 
Neurosci Res 85, 2741–2755.
Rangel A, Madronal N, Gruart A, Gavin R, Llorens F, Sumoy L, Torres JM, 
Delgado-Garcia JM, Del Rio JA (2009). Regulation of GABA(A) and glu-
tamate receptor expression, synaptic facilitation and long-term potentia-
tion in the hippocampus of prion mutant mice. PLoS One 4, e7592.
Roffe M et al. (2010). Prion protein interaction with stress-inducible protein 
1 enhances neuronal protein synthesis via mTOR. Proc Natl Acad Sci 
USA 107, 13147–13152.
Rutishauser D, Mertz KD, Moos R, Brunner E, Rulicke T, Calella AM, 
Aguzzi A (2009). The comprehensive native interactome of a fully func-
tional tagged prion protein. PLoS One 4, e4446.
3054 | P. Carulla et al. Molecular Biology of the Cell
Toscano CD, Kingsley PJ, Marnett LJ, Bosetti F (2008). NMDA-induced 
seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology 
29, 1114–1120.
Tu B, Bazan NG (2003). Hippocampal kindling epileptogenesis upregulates 
neuronal cyclooxygenase-2 expression in neocortex. Exp Neurol 179, 
167–175.
Vassallo N, Herms J (2003). Cellular prion protein function in copper 
homeostasis and redox signalling at the synapse. J Neurochem 86, 
538–544.
Verdoorn TA, Johansen TH, Drejer J, Nielsen EO (1994). Selective block of 
recombinant glur6 receptors by NS-102, a novel non-NMDA receptor 
antagonist. Eur J Pharmacol 269, 43–49.
Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, Goetz M, 
Lucius R, Herdegen T, Hanisch UK (2005). c-Jun N-terminal kinases 
(JNKs) mediate pro-inflammatory actions of microglia. Glia 50, 235–246.
Walz R, Amaral OB, Rockenbach IC, Roesler R, Izquierdo I, Cavalheiro EA, 
Martins VR, Brentani RR (1999). Increased sensitivity to seizures in mice 
lacking cellular prion protein. Epilepsia 40, 1679–1682.
Weise J, Crome O, Sandau R, Schulz-Schaeffer W, Bahr M, Zerr I (2004). 
Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia 
and influence of lesion severity. Neurosci Lett 372, 146–150.
Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, 
Zerr I, Bahr M (2006). Deletion of cellular prion protein results in reduced 
Akt activation, enhanced postischemic caspase-3 activation, and exacer-
bation of ischemic brain injury. Stroke 37, 1296–1300.
Weissmann C, Bueler H, Fischer M, Sailer A, Aguzzi A, Aguet M (1994). 
PrP-deficient mice are resistant to scrapie. Ann N Y Acad Sci 724, 235–240.
Westergard L, Christensen HM, Harris DA (2007). The cellular prion protein 
(PrP(C)): its physiological function and role in disease. Biochim Biophys 
Acta 1772, 629–644.
Wong BS et al. (2001). Increased levels of oxidative stress markers detected 
in the brains of mice devoid of prion protein. J Neurochem 76, 565–572.
Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, Rakic P, 
Flavell RA (1997). Absence of excitotoxicity-induced apoptosis in the 
hippocampus of mice lacking the Jnk3 gene. Nature 389, 865–870.
Zanata SM et al. (2002). Stress-inducible protein 1 is a cell surface ligand for 
cellular prion that triggers neuroprotection. EMBO J 21, 3307–3316.
Santuccione A, Sytnyk V, Leshchyns’ka I, Schachner M (2005). Prion protein 
recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and 
to enhance neurite outgrowth. J Cell Biol 169, 341–354.
Savinainen A, Garcia EP, Dorow D, Marshall J, Liu YF (2001). Kainate recep-
tor activation induces mixed lineage kinase-mediated cellular signal-
ing cascades via post-synaptic density protein 95. J Biol Chem 276, 
11382–11386.
Schmued LC, Hopkins KJ (2000). Fluoro-Jade: novel fluorochromes for 
detecting toxicant-induced neuronal degeneration. Toxicol Pathol 28, 
91–99.
Shyu WC et al. (2005). Hypoglycemia enhances the expression of prion 
protein and heat-shock protein 70 in a mouse neuroblastoma cell line. 
J Neurosci Res 80, 887–894.
Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, Bassetti CL, 
Hermann DM (2005). Aggravation of ischemic brain injury by prion 
protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis 20, 
442–449.
Steele AD (2008). All quiet on the neuronal front: NMDA receptor inhibition 
by prion protein. J Cell Biol 181, 407–409.
Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD (2006). Prion 
protein (PrPc) positively regulates neural precursor proliferation during 
developmental and adult mammalian neurogenesis. Proc Natl Acad Sci 
USA 103, 3416–3421.
Steele AD, Zhou Z, Jackson WS, Zhu C, Auluck P, Moskowitz MA, Chesselet 
MF, Lindquist S (2009). Context dependent neuroprotective properties 
of prion protein (PrP). Prion 3, 240–249.
Stoppini L, Buchs PA, Muller D (1991). A simple method for organotypic 
cultures of nervous tissue. J Neurosci Methods 37, 173–182.
Stoppini L, Buchs PA, Muller D (1993). Lesion-induced neurite sprouting and 
synapse formation in hippocampal organotypic cultures. Neuroscience 
57, 985–994.
Thais ME et al. (2006). Synaptosomal glutamate release and uptake in mice 
lacking the cellular prion protein. Brain Res 1075, 13–19.
Tian H, Zhang QG, Zhu GX, Pei DS, Guan QH, Zhang GY (2005). Activation 
of c-Jun NH2-terminal kinase 3 is mediated by the GluR6.PSD-95.MLK3 
signaling module following cerebral ischemia in rat hippocampus. Brain 
Res 1061, 57–66.
